Table 3.
Cytotoxic activities of momilactone-like molecules (IC50, μM)*
Compound | MDA-MB-435 | HT-29 | MDA-MB-231 | OVCAR3 | A2780 |
---|---|---|---|---|---|
Humirianthenolide C (11) | 0.66 | 3.00 | 0.67 | 1.05 | - |
2β-Humirianthenolide C (12) | 1.48 | - | 2.85 | 3.23 | - |
Humirianthol (16) | 1.65 | 4.94 | 3.74 | 4.12 | 3.0 |
15R-Humirianthol (17) | - | - | - | - | 2.2 |
14α-Methoxyhumirianthol (18) | 7.04 | - | 16.91 | 15.23 | - |
Acrenol (19) | - | - | - | - | 1.8 |
Humirianthone (20) | - | - | - | - | 6.1 |
Annonalide (22) | - | - | - | - | 3.9 |
Icacinol (24) | 1.25 | 4.23 | 7.30 | 7.55 | 1.7 |
17-Hydroxyicacinol (25) | 5.61 | 18.27 | - | - | - |
Icacenone (26) | 6.44 | 13.25 | 10.85 | 18.71 | - |
7α-Hydroxyicacenone (27) | 2.91 | - | 7.60 | 7.53 | - |
Icacinlactone F (37) | 6.16 | - | 8.94 | 10.5 | - |
MDA-MB-435: Human melanoma cell line; HT-29: Human colorectal adenocarcinoma epithelial cell line; MDA-MB-231: Human breast adenocarcinoma epithelial cell line; OVCAR3: Human ovarian adenocarcinoma epithelial cell line; A2780: Human ovarian cancer epithelial cell line. Compounds 25−29, 31−37 were inactive against MDA-MB-231, MDA-MB-435, and OVCAR3 (IC50 > 20 μM);